Advertisement

Topics

ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2alpha Antagonist, for the Treatment of Preterm Labor

09:00 EDT 28 Jul 2016 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
ObsEva SA / ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2alpha Antagonist, for the Treatment of Preterm Labor . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely respo...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2alpha Antagonist, for the Treatment of Preterm Labor"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Obstetrics and gynaecology
Fertility Menopause Obstetrics & Gynaecology Osteoporosis Women's Health Obstetrics and gynaecology comprises the care of the pregnant woman, her unborn child and the management of diseases specific to women. Most consultant...